Produktname:8-Chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine

IUPAC Name:8-chloro-2-(methylsulfanyl)pyrimido[5,4-d][1,3]diazine

CAS:176637-10-8
Molekulare Formel:C7H5ClN4S
Reinheit:95%+
Katalognummer:CM167362
Molekulargewicht:212.66

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM167362-250mg in stock ǠƚƐ
CM167362-500mg in stock ȤŸȤ
CM167362-1g in stock ŸƴŸ
CM167362-5g 1-2 Weeks ǠȋƐƐ
CM167362-10g 1-2 Weeks œȤƐȋ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:176637-10-8
Molekulare Formel:C7H5ClN4S
Schmelzpunkt:-
SMILES-Code:CSC1=NC=C(N=CN=C2Cl)C2=N1
Dichte:
Katalognummer:CM167362
Molekulargewicht:212.66
Siedepunkt:
Mdl-Nr.:MFCD00227587
Lagerung:Store at 2-8°C.

Column Infos

Zongertinib
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients.
Zongertinib (also known as BI 1810631) is an investigational oral HER2-specific tyrosine kinase inhibitor (TKI) that is being developed as a potential treatment for HER2 mutated non-small cell lung cancer (NSCLC). Zongertinib was granted FDA Fast Track Designation in 2023, then in 2024 it was granted Breakthrough Therapy Designation by the U.S. FDA and China CDE for the treatment of adult patients with advanced NSCLC whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.

Related Products